Disruptive Cryopreservation Technology

After 30 years of sub-standard one size fits all cryopreservation technology, the industry is about to change.

Evia Bio’s cryopreservation technology enables the entire cell and gene therapy supply chain, with higher cell yield and improved patient safety.

Current technology has set a well-established but not well-accepted low bar.

Very high dissatisfaction with DMSO which is the industry standard.

*Evia Bio primary research, 2020.

Researchers – You’re not alone.

Evia Eliminates All Critical Challenges

Pain Points

  • Loss of cell viability

  • Manufacturing disruption
  • Specificity by cell types

  • Patient safety

DMSO – Based/BioLife

  • 50% viability/ functionality; variable

  • Requires inefficient small batch manufacturing due to toxic nature of DMSO
  • Only one solution for all cell types; causes variable results
  • From nausea to cardiac failure
Our Osmolyte-based Solution

  • 85%+ viability/ functionality; consistent

  • No Issues

  • Optimized for each specific cell type; maximize results

  • No Issues

Therapy Supply Chain – DMSO limited

A typical cell therapy supply chain where the effectiveness of the therapy can depend on the viability of the original collected human cells

Step 1

Human cells collected from the patient or a donor (e.g., t-cells as part of a CAR-T)

Step 2

Because human cells cannot survive long outside the body without preservation, these delicate collected cells are preserved via cryopreservation for transport to a therapy manufacturing facility. With the toxic effects of DMSO, often only 50% of the original cell viability and functionality remains after the required freeze and thaw.

Step 3

The thawed cells are utilized for manufacture of a needed therapy. Again, cryopreservation is needed for the transport of the therapy containing the cells to the point of patient care.

Step 4

The therapy containing the cells is thawed in preparation for patient infusion. Again, the functionality and viability of the cells in the therapy are reduced due to the toxic nature of DMSO.

Step 5

The therapy that was preserved in DMSO, is infused into the patient, often resulting in patient safety issues ranging from nausea to sometime cardia arrest.

  • Step 1

    Human cells collected from the patient or a donor (e.g., t-cells as part of a CAR-T)

  • Step 2

    Because human cells cannot survive long outside the body without preservation, these delicate collected cells are preserved via cryopreservation for transport to a therapy manufacturing facility. With the toxic effects of DMSO, often only 50% of the original cell viability and functionality remains after the required freeze and thaw.

  • Step 3

    The thawed cells are utilized for manufacture of a needed therapy. Again, cryopreservation is needed for the transport of the therapy containing the cells to the point of patient care.

  • Step 4

    The therapy containing the cells is thawed in preparation for patient infusion. Again, the functionality and viability of the cells in the therapy are reduced due to the toxic nature of DMSO.

  • Step 5

    The therapy that was preserved in DMSO, is infused into the patient, often resulting in patient safety issues ranging from nausea to sometime cardia arrest.

DMSO technology damages cells, causes high cell losses during manufacturing and is harmful to patients.

Dimethylsulfoxide “DMSO”

  • Organic Industrial solvent

  • Manufacturing processes often result in cells being exposed to DMSO for extended periods of time

  • Patient infused with cells containing DMSO frequently have adverse reactions

© Evia Bio. All rights reserved.

Cell & Gene Therapy Solutions

Discuss Clinical Applications
Talk More? Contact Us Here

Office

2001 6th St. SE
Room 2-434, Bench 33
Minneapolis, MN 55455
1-888-594-0411